Antithrombin III for critically ill patients.

Area of Science:

• Critical care medicine
• Pharmacology
• Intensive care research

Background:

• Critical illness involves uncontrolled inflammation and vascular damage, potentially leading to organ failure and death.
• Antithrombin III (AT III) possesses anticoagulant and anti-inflammatory properties, but its use in critical care is not well-established.

Purpose of the Study:

• To evaluate the efficacy and safety of Antithrombin III (AT III) supplementation in critically ill patients.
• To assess the benefits and harms of AT III in this patient population.

Main Methods:

• Conducted a systematic review and meta-analysis of 20 randomized clinical trials involving 3458 critically ill patients.
• Primary outcome was mortality; subgroup analyses examined risk of bias, patient populations, and concomitant heparin use.
• Data were collected and analyzed using standard meta-analytic techniques, including relative risks and confidence intervals.

Main Results:

• Antithrombin III (AT III) did not significantly reduce overall mortality (RR 0.96, 95% CI 0.89 to 1.03).
• Subgroup analyses did not reveal significant differences based on risk of bias, patient type, or heparin use.
• AT III supplementation was associated with a significant increase in bleeding events (RR 1.52, 95% CI 1.30 to 1.78).

Conclusions:

• Current evidence does not support the recommendation of Antithrombin III (AT III) for critically ill patients.
• Further high-quality randomized controlled trials are needed to clarify the role of AT III, particularly without concomitant heparin.